Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing100021, People's Republic of China.
Department of Interventional Radiology, First Hospital of Shanxi Medical University, Shanxi Province, Taiyuan030001, People's Republic of China.
Br J Nutr. 2022 Nov 28;128(10):1966-1974. doi: 10.1017/S000711452100492X. Epub 2021 Dec 9.
This retrospective study investigated the predictive value of the Controlling Nutritional Status (CONUT) score in patients with intermediate-stage hepatocellular carcinoma (HCC) who received transarterial chemoembolization (TACE). Nomograms were developed to predict progression-free and overall survival (PFS, OS). The medical data of 228 patients with HCC and treated with TACE were collected. The patients were apportioned to 2 groups according to CONUT score: low or high (<4, ≥4). Univariate and multivariate analyses were performed using Cox regression for OS and PFS. OS and PFS were estimated by the Kaplan-Meier curve and compared with the log-rank test. Nomograms were constructed to predict patient OS and PFS. The nomograms were evaluated for accuracy, discrimination, and efficiency. The cut-off value of CONUT score was 4. The higher the CONUT score, the worse the survival; Kaplan-Meier curves showed significant differences in OS and PFS between the low and high CONUT score groups ( = 0·033, 0·047). The nomograms including CONUT, based on the prognostic factors determined by the univariate and multivariate analyses, to predict survival in HCC after TACE were generated. The CONUT score is an important prognostic factor for both OS and PFS for patients with intermediate HCC who underwent TACE. The cut-off value of the CONUT score was 4. A high CONUT score suggests poor survival outcomes. Nomograms generated based on the CONUT score were good models to predict patient OS and PFS.
本回顾性研究探讨了控制营养状况(CONUT)评分在接受经动脉化疗栓塞(TACE)治疗的中期肝细胞癌(HCC)患者中的预测价值。建立了列线图来预测无进展生存期(PFS)和总生存期(OS)。收集了 228 例接受 TACE 治疗的 HCC 患者的医学数据。根据 CONUT 评分将患者分为两组:低或高(<4,≥4)。使用 Cox 回归进行单因素和多因素分析以评估 OS 和 PFS。通过 Kaplan-Meier 曲线和对数秩检验估计 OS 和 PFS。构建列线图预测患者的 OS 和 PFS。评估了列线图的准确性、区分度和效率。CONUT 评分的截断值为 4。CONUT 评分越高,生存越差;Kaplan-Meier 曲线显示低 CONUT 评分组和高 CONUT 评分组之间 OS 和 PFS 存在显著差异(=0·033,0·047)。基于单因素和多因素分析确定的预后因素,生成了包含 CONUT 的列线图,以预测 HCC 患者 TACE 后的生存情况。CONUT 评分是 TACE 治疗中期 HCC 患者 OS 和 PFS 的重要预后因素。CONUT 评分的截断值为 4。高 CONUT 评分提示预后不良。基于 CONUT 评分生成的列线图是预测患者 OS 和 PFS 的良好模型。